Evidence map›Paper›PMID 26551670›Full record

ArticleNature genetics2015

Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.

Linghua Wang, Xiao Ni, Kyle R Covington, Betty Y Yang, Jessica Shiu, Xiang Zhang, Liu Xi, Qingchang Meng, Timothy Langridge, Jennifer Drummond and 6 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 1 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 1 synthesis or guideline pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Linghua WangHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Xiao NiDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kyle R CovingtonHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Betty Y YangDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jessica ShiuDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiang ZhangDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Liu XiHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Qingchang MengHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Timothy LangridgeDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer DrummondHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-2612-5958
Lawrence A DonehowerDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Harshavardhan DoddapaneniHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Donna M MuznyHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Richard A GibbsHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Madeleine DuvicDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS CA16672NCI NIH HHS P30 CA016672NHGRI NIH HHS 5U54HG003273NHGRI NIH HHS U54 HG003273
6 · The paper itself

Abstract

Sézary syndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized redness, scaling, itching and increased numbers of circulating atypical T lymphocytes. It is rarely curable, with poor prognosis. Here we present a multiplatform genomic analysis of 37 patients with Sézary syndrome that implicates dysregulation of cell cycle checkpoint and T cell signaling. Frequent somatic alterations were identified in TP53, CARD11, CCR4, PLCG1, CDKN2A, ARID1A, RPS6KA1 and ZEB1. Activating CCR4 and CARD11 mutations were detected in nearly one-third of patients. ZEB1, encoding a transcription repressor essential for T cell differentiation, was deleted in over one-half of patients. IL32 and IL2RG were overexpressed in nearly all cases. Our results demonstrate profound disruption of key signaling pathways in Sézary syndrome and suggest potential targets for new therapies.

Indexed as

Gene Regulatory NetworksCase-Control StudiesCell DifferentiationExomeGene Expression Regulation, NeoplasticGenetic DriftGenomicsHigh-Throughput Nucleotide SequencingHumansLymphocyte ActivationMutationPrognosisSezary SyndromeSignal TransductionSkin NeoplasmsSurvival Rate

Identifiers

PMID26551670
PMCPMC4829974
OpenAlexW2195886524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.